{"preliminary_commentary":{"by_channel":{"youtube":19,"podcast":17,"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05173987\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"KEYNOTE-C93","nct_id":"NCT05173987","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=keynote-c93-nct05173987. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive pembrolizumab 400 mg via IV infusion on Day 1 of each 6-week cycle (Q6W) for up to 18 cycles (up to approximately 2 years).","label":"Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Participants receive a combination of paclitaxel 175 mg/m\\^2 on Day 1 of each 3-week cycle (Q3W) and carboplatin AUC 5 or 6 on Day 1 Q3W for 6 cycles (up to approximately 4 months). Participants who experience a severe hypersensitivity reaction to paclitaxel or an adverse event (AE) requiring discontinuation of paclitaxel may receive docetaxel 75 mg/m\\^2 in place of paclitaxel on Day 1 Q3W after Sponsor consultation. Participants who experience a severe hypersensitivity reaction to carboplatin or an AE requiring discontinuation of carboplatin may receive cisplatin 75 mg/m\\^2 in place of carboplatin on Day 1 Q3W after Sponsor consultation.","label":"Carboplatin+paclitaxel","type":"ACTIVE_COMPARATOR"}],"collaborators":["European Network of Gynaecological Oncological Trial Groups (ENGOT)","GOG Foundation"],"completion_date":{"date":"2027-05-27","type":"ESTIMATED"},"conditions":["Endometrial Neoplasms"],"enrollment":{"count":280,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"pembrolizumab","otherNames":["KEYTRUDA®","MK-3475"],"type":"BIOLOGICAL"},{"name":"carboplatin","otherNames":["PARAPLATIN®"],"type":"DRUG"},{"name":"paclitaxel","otherNames":["TAXOL®"],"type":"DRUG"},{"name":"docetaxel","otherNames":["TAXOTERE®"],"type":"DRUG"},{"name":"cisplatin","otherNames":["PLATINOL-AQ®"],"type":"DRUG"}],"last_update":"2026-05-05","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-05-27","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to approximately 45 months"},{"measure":"Overall Survival","timeFrame":"Up to approximately 59 months"}],"references":[{"citation":"McClain KM, Prabhu VS, Marupuru S, Meng K, Tran V, Orlowski R, Meng R, Green AK, Makker V. Real-world outcomes of first-line pembrolizumab monotherapy among dMMR/MSI-H advanced or recurrent endometrial cancer patients in the United States. Gynecol Oncol. 2026 Oct 9:S0090-8258(26)02101-3. doi: 10.1016/j.ygyno.2026.08.009. Online ahead of print.","pmid":"42855328","type":"DERIVED"},{"citation":"Secord AA, Powell MA, McAlpine J. Molecular Characterization and Clinical Implications of Endometrial Cancer. Obstet Gynecol. 2025 Nov 1;146(5):660-671. doi: 10.1097/AOG.0000000000006080. Epub 2025 Sep 18.","pmid":"40966692","type":"DERIVED"}],"start_date":{"date":"2022-02-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)","url":"https://clinicaltrials.gov/study/NCT05173987"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/keynote-c93-nct05173987"}